{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:41:04Z","timestamp":1788716464626,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10067-019-04866-x","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T11:04:56Z","timestamp":1578049496000},"page":"1439-1447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-0771","authenticated-orcid":false,"given":"Nat\u00e1lia Sarzi","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Pamplona Bueno","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Mendon\u00e7a","family":"da Silva Chakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"issue":"5 SUPPL","key":"4866_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","volume":"34","author":"RS Wallis","year":"2005","unstructured":"Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34(5 SUPPL):34\u201338. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.01.009","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"4866_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5433\/1679-0367.2011v32n1p77","volume":"32","author":"LR Faleiro","year":"2011","unstructured":"Faleiro LR, Araujo LHR, Varavallo MA (2011) A terapia anti-TNF-a na artrite reumat\u00f3ide. Semina: Ci\u00eanc Biol Sa\u00fade 32(1):77\u201394. https:\/\/doi.org\/10.5433\/1679-0367.2011v32n1p77","journal-title":"Semina: Ci\u00eanc Biol Sa\u00fade"},{"key":"4866_CR3","unstructured":"Firestein GS, Budd RC, Gabriel SE, McInnes IB, O\u2019Dell J (2013) Kelley\u2019s textbook of rheumatology. Vol Ninth. (Elsevier, ed.).Philadelphia"},{"key":"4866_CR4","unstructured":"Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman M (2015) Rheumatology Vol Sixth. (Elsevier, ed.). Philadelphia"},{"key":"4866_CR5","unstructured":"World Health Organization (2018) Global tuberculosis report 2018 [Internet]. Geneva: World Health Organization. Available from: Available from: http:\/\/apps.who.int\/medicinedocs\/en\/m\/abstract\/Js23553en\/"},{"issue":"9194","key":"4866_CR6","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(99)05246-0","journal-title":"Lancet"},{"issue":"2","key":"4866_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Van Der Heijde","year":"2005","unstructured":"Van Der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582\u2013591. https:\/\/doi.org\/10.1002\/art.20852","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4866_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, B S R B R Control Centre Consortium, Symmons DP, BSR Biologics Register (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69(3):522\u2013528. https:\/\/doi.org\/10.1136\/ard.2009.118935","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4866_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/1756-185X.12375","volume":"17","author":"R Scrivo","year":"2014","unstructured":"Scrivo R, Armignacco O (2014) Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data. Int J Rheum Dis 17(7):714\u2013722. https:\/\/doi.org\/10.1111\/1756-185X.12375","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"4866_CR10","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, G\u00f3mez-Reino JJ, Rodr\u00edguez-Valverde V, Montero D, Pascual-G\u00f3mez E, Mola EM, Carre\u00f1o L, Figueroa M, BIOBADASER Group (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766\u20131772. https:\/\/doi.org\/10.1002\/art.21043","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4866_CR11","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Br\u00e9ban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X, Research Axed on Tolerance of Biotherapies Group (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 60(7):1884\u20131894. https:\/\/doi.org\/10.1002\/art.24632","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4866_CR12","first-page":"706","volume":"34","author":"S-S Seong","year":"2007","unstructured":"Seong S-S, Choi C-B, Woo J-H, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC (2007) Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 34(4):706\u2013711 http:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-34247332718&partnerID=40&md5=37282bf3735840802a493e16fce30fa9. Accessed Aug 2018","journal-title":"J Rheumatol"},{"issue":"4","key":"4866_CR13","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/crj.12726","volume":"12","author":"T Cagatay","year":"2018","unstructured":"Cagatay T, Bingol Z, K\u0131yan E, Yegin Z, Okumus G, Arseven O, Erkan F, Gulbaran Z, Erelel M, Ece T, Cagatay P, K\u0131l\u0131\u00e7aslan Z (2018) Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: tuberculin skin test conversion and tuberculosis risk. Clin Respir J 12(4):1668\u20131675. https:\/\/doi.org\/10.1111\/crj.12726","journal-title":"Clin Respir J"},{"issue":"12","key":"4866_CR14","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3899\/jrheum.150057","volume":"42","author":"J-W Ai","year":"2015","unstructured":"Ai J-W, Zhang S, Ruan Q-L, Yu YQ, Zhang BY, Liu QH, Zhang WH (2015) The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor- antagonist: a metaanalysis of both randomized controlled trials and registry\/cohort studies. J Rheumatol 42(12):2229\u20132237. https:\/\/doi.org\/10.3899\/jrheum.150057","journal-title":"J Rheumatol"},{"key":"4866_CR15","doi-asserted-by":"publisher","unstructured":"Zhang Z, Fan W, Yang G et al (2017) Risk of tuberculosis in patients treated with TNF- \u03b1 antagonists : a systematic review and meta-analysis of randomised controlled trials. https:\/\/doi.org\/10.1136\/bmjopen-2016-012567","DOI":"10.1136\/bmjopen-2016-012567"},{"issue":"S 2","key":"4866_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.rbr.2017.05.003","volume":"57","author":"CL Yonekura","year":"2017","unstructured":"Yonekura CL, Oliveira RDR, Titton DC et al (2017) Incid\u00eancia de tuberculose em pacientes com artrite reumatoide em uso de bloqueadores do TNF no Brasil: dados do Registro Brasileiro de Monitora\u00e7\u00e3o de Terapias Biol\u00f3gicas BiobadaBrasil. Rev Bras Reumatol 57(S 2):477\u2013483. https:\/\/doi.org\/10.1016\/j.rbr.2017.05.003","journal-title":"Rev Bras Reumatol"},{"issue":"6","key":"4866_CR17","doi-asserted-by":"publisher","first-page":"e0178035","DOI":"10.1371\/journal.pone.0178035","volume":"12","author":"CH Lim","year":"2017","unstructured":"Lim CH, Chen H-H, Chen Y-H, Chen DY, Huang WN, Tsai JJ, Hsieh TY, Hsieh CW, Hung WT, Lin CT, Lai KL, Tang KT, Tseng CW, Chen YM (2017) The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan. PLoS One 12(6):e0178035. https:\/\/doi.org\/10.1371\/journal.pone.0178035","journal-title":"PLoS One"},{"issue":"8","key":"4866_CR18","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s10067-017-3714-6","volume":"36","author":"G Garziera","year":"2017","unstructured":"Garziera G, Morsch ALB, Otesbelgue F, Staub FL, Palominos PE, Brenol CV, Silva DR (2017) Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents. Clin Rheumatol 36(8):1891\u20131896. https:\/\/doi.org\/10.1007\/s10067-017-3714-6","journal-title":"Clin Rheumatol"},{"issue":"11","key":"4866_CR19","doi-asserted-by":"publisher","first-page":"e0166339","DOI":"10.1371\/journal.pone.0166339","volume":"11","author":"C-H Lim","year":"2016","unstructured":"Lim C-H, Lin C-H, Chen D-Y, Chen YM, Chao WC, Liao TL, Chen HH (2016) One-year tuberculosis risk in rheumatoid arthritis patients starting their first tumor necrosis factor inhibitor therapy from 2008 to 2012 in Taiwan: a nationwide population-based cohort study. PLoS One 11(11):e0166339. https:\/\/doi.org\/10.1371\/journal.pone.0166339","journal-title":"PLoS One"},{"issue":"4","key":"4866_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0153217","volume":"11","author":"TL Liao","year":"2016","unstructured":"Liao TL, Lin CH, Chen YM, Chang CL, Chen HH, Chen DY (2016) Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in Taiwan. PLoS One 11(4):1\u201314. https:\/\/doi.org\/10.1371\/journal.pone.0153217","journal-title":"PLoS One"},{"issue":"3","key":"4866_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3899\/jrheum.150177","volume":"43","author":"B Kisacik","year":"2016","unstructured":"Kisacik B, Pamuk ON, Onat AM, Erer SB, Hatemi G, Ozguler Y, Pehlivan Y, Kilic L, Ertenli I, Can M, Direskeneli H, Keser G, Oksel F, Dalkilic E, Yilmaz S, Pay S, Balkarli A, Cobankara V, Cetin GY, Sayarlioglu M, Cefle A, Yazici A, Avci AB, Terzioglu E, Ozbek S, Akar S, Gul A (2016) Characteristics predicting tuberculosis risk under tumor necrosis factor-\u03b1 inhibitors: report from a large multicenter cohort with high background prevalence. J Rheumatol 43(3):524\u2013529. https:\/\/doi.org\/10.3899\/jrheum.150177","journal-title":"J Rheumatol"},{"issue":"1","key":"4866_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5588\/ijtld.15.0283","volume":"20","author":"A Watanabe","year":"2016","unstructured":"Watanabe A, Matsumoto T, Igari H, Sawa J, Yamaguchi Y, Sakatani M (2016) Risk of developing active tuberculosis in rheumatoid arthritis patients on adalimumab in Japan. Int J Tuberc Lung Dis 20(1):101\u2013108. https:\/\/doi.org\/10.5588\/ijtld.15.0283","journal-title":"Int J Tuberc Lung Dis"},{"key":"4866_CR23","doi-asserted-by":"publisher","unstructured":"Rotar \u017d, Tomsic M (2016) Incidence rate of tuberculosis in rheumatoid arthritis patients treated with TNF-\u03b1 inhibitors-data from the slovenian national BioRx.si registry, Ann Rheum Dis. 75:1016\u20131017. https:\/\/doi.org\/10.1136\/annrheumdis-2016-eular.1903","DOI":"10.1136\/annrheumdis-2016-eular.1903"},{"issue":"4","key":"4866_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2015-009661","volume":"6","author":"P Rahman","year":"2016","unstructured":"Rahman P, Choquette D, Bensen WG, Khraishi M, Chow A, Zummer M, Shaikh S, Sheriff M, Dixit S, Sholter D, Psaradellis E, Sampalis JS, Letourneau V, Lehman AJ, Nantel F, Rampakakis E, Otawa S, Shawi M (2016) Biologic treatment registry across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis. BMJ Open 6(4):1\u201310. https:\/\/doi.org\/10.1136\/bmjopen-2015-009661","journal-title":"BMJ Open"},{"issue":"4","key":"4866_CR25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/rheumatology\/kev398","volume":"55","author":"AF Mour\u00e3o","year":"2016","unstructured":"Mour\u00e3o AF, Santos MJ, Melo Gomes JA, Martins FM, Mendon\u00e7a SC, Oliveira Ramos F, Fernandes S, Salgado M, Guedes M, Carvalho S, Costa JA, Brito I, Duarte C, Furtado C, Lopes A, Rodrigues A, Sequeira G, Branco JC, Fonseca JE, Canh\u00e3o H (2016) Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Pediatr Rheumatol Online J 55(4):697\u2013703. https:\/\/doi.org\/10.1093\/rheumatology\/kev398","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"4866_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12969-015-0054-4","volume":"13","author":"J Calzada-Hern\u00e1ndez","year":"2015","unstructured":"Calzada-Hern\u00e1ndez J, Anton-L\u00f3pez J, Bou-Torrent R, Iglesias-Jim\u00e9nez E, Ricart-Campos S, Mart\u00edn de Carpi J, Carmen Garc\u00eda de Vicu\u00f1a Mu\u00f1oz de la Nava, Torrente-Segarra V, S\u00e1nchez-Manubens J, Gim\u00e9nez-Roca C, Rozas-Quesada L, Juncosa-Morros MT, Fortuny C, Noguera-Julian A (2015) Tuberculosis in pediatric patients treated with anti-TNF\u03b1 drugs: a cohort study. Pediatr Rheumatol Online J 13(1):54. https:\/\/doi.org\/10.1186\/s12969-015-0054-4","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"4866_CR27","doi-asserted-by":"publisher","first-page":"e0128768","DOI":"10.1371\/journal.pone.0128768","volume":"10","author":"Y-C Hsin","year":"2015","unstructured":"Hsin Y-C, Zhuang L-Z, Yeh K-W, Chang C-W, Horng J-T, Huang J-L (2015) Risk of tuberculosis in children with juvenile idiopathic arthritis: a nationwide population-based study in Taiwan. PLoS One 10(6):e0128768. https:\/\/doi.org\/10.1371\/journal.pone.0128768","journal-title":"PLoS One"},{"issue":"3","key":"4866_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/1756-185X.12530","volume":"18","author":"SM Jung","year":"2015","unstructured":"Jung SM, Ju JH, Park M-S, Kwok SK, Park KS, Kim HY, Yim HW, Park SH (2015) Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden. Int J Rheum Dis 18(3):323\u2013330. https:\/\/doi.org\/10.1111\/1756-185X.12530","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"4866_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000434684","volume":"90","author":"S Borekci","year":"2015","unstructured":"Borekci S, Atahan E, Demir Yilmaz D, Maz\u0131can N, Duman B et al (2015) Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-\u03b1 treatment. Respiration 90(3):191\u2013198. https:\/\/doi.org\/10.1159\/000434684","journal-title":"Respiration"},{"issue":"7","key":"4866_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1590\/0074-02760150235","volume":"110","author":"CMF Gomes","year":"2015","unstructured":"Gomes CMF, Terreri MT, de Moraes-Pinto MI et al (2015) Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline-a longitudinal analysis after using TNF\u03b1 blockers. Mem Inst Oswaldo Cruz 110(7):921\u2013928. https:\/\/doi.org\/10.1590\/0074-02760150235","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"s3","key":"4866_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/1756-185X.12539","volume":"17","author":"YM Chiu","year":"2014","unstructured":"Chiu YM, Lang HC, Lin HY et al (2014) Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis 17(s3):9\u201319. https:\/\/doi.org\/10.1111\/1756-185X.12539","journal-title":"Int J Rheum Dis"},{"issue":"Suppl. 3","key":"4866_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1756-185X.12264","volume":"17","author":"C Mok","year":"2014","unstructured":"Mok C, Chan K, Lee K, Tam L, Lee K (2014) Factors associated with withdrawal of the anti-TNFa biologics in the treatment of rheumatic disease: data from the Hong Kong Biologics Registry. Int J Rheum Dis 17(Suppl. 3):1\u20138. https:\/\/doi.org\/10.1111\/1756-185X.12264","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"4866_CR33","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1183\/09031936.00063514","volume":"44","author":"JW Yoo","year":"2014","unstructured":"Yoo JW, Jo KW, Kang BH, Kim MY, Yoo B et al (2014) Mycobacterial diseases developed during anti-tumour necrosis factor-a therapy. Eur Respir J 44(5):1289\u20131295. https:\/\/doi.org\/10.1183\/09031936.00063514","journal-title":"Eur Respir J"},{"issue":"12","key":"4866_CR34","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.5588\/ijtld.13.0368","volume":"17","author":"W-M Ke","year":"2013","unstructured":"Ke W-M, Chen L-S, Parng I-M, Chen W-W, On AWF (2013) Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. Int J Tuberc Lung Dis 17(12):1590\u20131595. https:\/\/doi.org\/10.5588\/ijtld.13.0368","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"4866_CR35","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00408-013-9481-5","volume":"191","author":"SK Lee","year":"2013","unstructured":"Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Kang YA (2013) Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lung 191(5):565\u2013571. https:\/\/doi.org\/10.1007\/s00408-013-9481-5","journal-title":"Lung"},{"key":"4866_CR36","doi-asserted-by":"publisher","unstructured":"Sarychev A, Shovkun L (2013) PReS-FINAL-2019: tuberculosis infection observed in patients receiving biological DMARDs for treatment of juvenile idiopathic arthritis. Pediatr Rheumatol 11. https:\/\/doi.org\/10.1186\/1546-0096-11-S2-P32","DOI":"10.1186\/1546-0096-11-S2-P32"},{"key":"4866_CR37","doi-asserted-by":"publisher","unstructured":"\u017dlnay M, \u017dlnay D, Salkova M, Oetterov\u00e1 M, Mi\u010dekov\u00e1 D, Barancikova K, Rovensk\u00fd J, Ryb\u00e1r I (2013) The risk of tuberculosis in patients with ankylosing spondylitis during anti-TNF therapy: data from national database in Slovakia. Ann Rheum Dis 72. https:\/\/doi.org\/10.1136\/annrheumdis-2013-eular.1541","DOI":"10.1136\/annrheumdis-2013-eular.1541"},{"issue":"6","key":"4866_CR38","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1128\/CVI.00049-13","volume":"20","author":"D He","year":"2013","unstructured":"He D, Bai F, Zhang S, Jiang T, Shen J et al (2013) High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy. Clin Vaccine Immunol 20(6):892\u2013899. https:\/\/doi.org\/10.1128\/CVI.00049-13","journal-title":"Clin Vaccine Immunol"},{"issue":"9","key":"4866_CR39","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s10067-013-2387-z","volume":"33","author":"HW Kim","year":"2014","unstructured":"Kim HW, Park JK, Yang JA, Yoon YI, Lee EY, Song YW, Kim HR, Lee EB (2014) Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area. Clin Rheumatol 33(9):1307\u20131312. https:\/\/doi.org\/10.1007\/s10067-013-2387-z","journal-title":"Clin Rheumatol"},{"issue":"11","key":"4866_CR40","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.rmed.2013.08.011","volume":"107","author":"KW Jo","year":"2013","unstructured":"Jo KW, Hong Y, Jung YJ, Yoo B, Lee CK et al (2013) Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis. Respir Med 107(11):1797\u20131802. https:\/\/doi.org\/10.1016\/j.rmed.2013.08.011","journal-title":"Respir Med"},{"key":"4866_CR41","doi-asserted-by":"publisher","unstructured":"Calzada-Hern\u00e1ndez J, Julian AN, Campos SR, Torrent RB, Jim\u00e9nez EI et al (2013) PReS-FINAL-2265: tuberculosis in pediatric patients who are receiving anti-TNF agents. Pediatr Rheumatol 11. https:\/\/doi.org\/10.1186\/1546-0096-11-S2-P255","DOI":"10.1186\/1546-0096-11-S2-P255"},{"issue":"1","key":"4866_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","volume":"72","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum JT, Herrinton LJ (2013) Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72(1):37\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200690","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4866_CR43","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3899\/jrheum.111555","volume":"39","author":"C Bracaglia","year":"2012","unstructured":"Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A, Insalaco A, Cortis E, de Benedetti F (2012) Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J Rheumatol 39(6):1287\u20131290. https:\/\/doi.org\/10.3899\/jrheum.111555","journal-title":"J Rheumatol"},{"issue":"11","key":"4866_CR44","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2012-201913","volume":"71","author":"M Tomsic","year":"2012","unstructured":"Tomsic M, Rotar Z (2012) The frequency of tuberculosis chemoprophylaxis prior to TNF-\u03b1 inhibitor treatment, and the incidence tuberculosis infection using a two-step screening algorithm for latent tuberculosis infection: data from the BioRx.si registry. Ann Rheum Dis 71(11):1909\u20131911. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201913","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4866_CR45","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.3899\/jrheum.110373","volume":"38","author":"E-M Kim","year":"2011","unstructured":"Kim E-M, Uhm W-S, Bae S-C, Yoo D-H, Kim T-H (2011) Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 38(10):2218\u20132223. https:\/\/doi.org\/10.3899\/jrheum.110373","journal-title":"J Rheumatol"},{"issue":"9","key":"4866_CR46","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00296-011-2017-5","volume":"32","author":"CA Nobre","year":"2012","unstructured":"Nobre CA, Callado MRM, Lima JRC, Gomes KWP (2012) Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients. Rheumatol Int 32(9):2769\u20132775. https:\/\/doi.org\/10.1007\/s00296-011-2017-5","journal-title":"Rheumatol Int"},{"issue":"9","key":"4866_CR47","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1007\/s00296-011-2030-8","volume":"32","author":"O Kilic","year":"2012","unstructured":"Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N (2012) Is it safe to use anti-TNF-alpha agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int 32(9):2675\u20132679. https:\/\/doi.org\/10.1007\/s00296-011-2030-8","journal-title":"Rheumatol Int"},{"issue":"2","key":"4866_CR48","first-page":"145","volume":"51","author":"DC Titton","year":"2011","unstructured":"Titton DC, Silveira IG, Louzada-junior P et al (2011) Registro Brasileiro de Biol\u00f3gicos : preliminares do BiobadaBrasil. Rev Bras Reumatol 51(2):145\u2013160","journal-title":"Rev Bras Reumatol"},{"issue":"12","key":"4866_CR49","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.medcli.2010.11.032","volume":"137","author":"MJ P\u00e9rez-Sola","year":"2011","unstructured":"P\u00e9rez-Sola MJ, Torre-Cisneros J, P\u00e9rez-Zafrilla B, Carmona L, Descalzo MA, G\u00f3mez-Reino JJ (2011) Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc) 137(12):533\u2013540. https:\/\/doi.org\/10.1016\/j.medcli.2010.11.032","journal-title":"Med Clin (Barc)"},{"key":"4866_CR50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1756-185X.2010.01498.x","volume":"13","author":"MI Liza","year":"2010","unstructured":"Liza MI, Lim AL, H H, G SC (2010) Anti-TNFa therapy and tuberculosis risk : a two-centre experience. Int J Rheum Dis 13:90. https:\/\/doi.org\/10.1111\/j.1756-185X.2010.01498.x","journal-title":"Int J Rheum Dis"},{"key":"4866_CR51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/03009742.2010.530485","volume":"39","author":"K Laas","year":"2010","unstructured":"Laas K, Savi T, O K (2010) Active tuberculosis among patients with inflammatory rheumatic diseases treated with TNF-\u03b1 inhibitors in a rheumatology center in Estonia. Scand J Rheumatol 39:32. https:\/\/doi.org\/10.3109\/03009742.2010.530485","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"4866_CR52","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00296-009-1170-6","volume":"30","author":"T Cagatay","year":"2010","unstructured":"Cagatay T, Aydin M, Sunmez S, Cagatay P, Gulbaran Z, Gul A, Artim B, Kilicaslan Z (2010) Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int 30(11):1459\u20131463. https:\/\/doi.org\/10.1007\/s00296-009-1170-6","journal-title":"Rheumatol Int"},{"issue":"4","key":"4866_CR53","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10067-008-1067-x","volume":"28","author":"O Elbek","year":"2009","unstructured":"Elbek O, Uyar M, Aydin N et al (2009) Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha. Clin Rheumatol 28(4):421\u2013426. https:\/\/doi.org\/10.1007\/s10067-008-1067-x","journal-title":"Clin Rheumatol"},{"issue":"3","key":"4866_CR54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","volume":"8","author":"EG Favalli","year":"2009","unstructured":"Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, Gorla R, Filippini M, Marchesoni A (2009) Serious infections during anti-TNF?? Treatment in rheumatoid arthritis patients. Autoimmun Rev 8(3):266\u2013273. https:\/\/doi.org\/10.1016\/j.autrev.2008.11.002","journal-title":"Autoimmun Rev"},{"issue":"4","key":"4866_CR55","first-page":"164","volume":"109","author":"I Rybar","year":"2008","unstructured":"Rybar I, Rozborilova E, Zanova E, Micekova D, Solovic I, Rovensky J (2008) The effectiveness for prevention of tuberculosis in patients with inflammatory rheumatic diseases treated with TNF inhibitors. Bratisl Lek Listy 109(4):164\u2013167 http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id=L352509877. Accessed Aug 2018","journal-title":"Bratisl Lek Listy"},{"issue":"4","key":"4866_CR56","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10096-008-0628-x","volume":"28","author":"C Garcia-Vidal","year":"2009","unstructured":"Garcia-Vidal C, Rodr\u00edguez-Fern\u00e1ndez S, Teij\u00f3n S, Esteve M, Rodr\u00edguez-Carballeira M, Lacasa JM, Salvador G, Garau J (2009) Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 28(4):331\u2013337. https:\/\/doi.org\/10.1007\/s10096-008-0628-x","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"4866_CR57","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/art.22768","volume":"57","author":"JJ Gomez-Reino","year":"2007","unstructured":"Gomez-Reino JJ, Carmona L, Angel Descalzo M (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57(5):756\u2013761. https:\/\/doi.org\/10.1002\/art.22768","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4866_CR58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0973-3698(10)60021-0","volume":"2","author":"K Narayanan","year":"2007","unstructured":"Narayanan K, Anand KP (2007) Long-term follow up of infliximab therapy in inflammatory arthritis. Indian J Rheumatol 2(1):8\u201310 http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id=L351266264. Accessed Aug 2018","journal-title":"Indian J Rheumatol"},{"issue":"2","key":"4866_CR59","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard.2007.072967","volume":"67","author":"T Takeuchi","year":"2008","unstructured":"Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67(2):189\u2013194. https:\/\/doi.org\/10.1136\/ard.2007.072967","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4866_CR60","first-page":"1127","volume":"10","author":"L Sichletidis","year":"2006","unstructured":"Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D (2006) Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10(10):1127\u20131132","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"4866_CR61","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1086\/506935","volume":"43","author":"P Brassard","year":"2006","unstructured":"Brassard P, Kezouh A, Suissa S (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43(6):717\u2013722. https:\/\/doi.org\/10.1086\/506935","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4866_CR62","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1002\/art.21137","volume":"52","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, C\u00f6ster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantap\u00e4\u00e4-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52(7):1986\u20131992. https:\/\/doi.org\/10.1002\/art.21137","journal-title":"Arthritis Rheum"},{"issue":"suppl 1","key":"4866_CR63","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.aprim.2009.04.011","volume":"60","author":"I Strusberg","year":"2000","unstructured":"Strusberg I et al (2000) Uso de infliximab en pacientes de un centro reumatologico\/use of infliximab in patients of a rheumatologic center. Med (Buenos Aires) 60(suppl 1):561\u2013564. https:\/\/doi.org\/10.1016\/j.aprim.2009.04.011","journal-title":"Med (Buenos Aires)"},{"issue":"2","key":"4866_CR64","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/art.20009","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K, Anderson J, Urbansky K (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50(2):372\u2013379. https:\/\/doi.org\/10.1002\/art.20009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4866_CR65","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ G\u00f3mez-Reino","year":"2003","unstructured":"G\u00f3mez-Reino JJ, Carmona L, Rodr\u00edguez Valverde V, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122\u20132127. https:\/\/doi.org\/10.1002\/art.11137","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4866_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Sch\u00f6ls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landew\u00e9 R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes I, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77(1):3\u201317. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211734","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4866_CR67","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/BOR.0b013e32832c792d","volume":"21","author":"N Haroon","year":"2009","unstructured":"Haroon N, Inman RD (2009) Infectious complications of biological therapy. Curr Opin Rheumatol 21(4):397\u2013403. https:\/\/doi.org\/10.1097\/BOR.0b013e32832c792d","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"4866_CR68","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/03009742.2016.1202318","volume":"46","author":"YM Chiu","year":"2017","unstructured":"Chiu YM, Tang CH, Hung ST, Yang YW, Fang CH, Lin HY (2017) A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. Scand J Rheumatol 46(3):236\u2013240. https:\/\/doi.org\/10.1080\/03009742.2016.1202318","journal-title":"Scand J Rheumatol"},{"key":"4866_CR69","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/1756-185X.12188","volume":"17","author":"SV Navarra","year":"2014","unstructured":"Navarra SV, Tang B, Lin H-Y et al (2014) Risk of tuberculosis with anti-tumor necrosis factor-a therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis 17:291\u2013298. https:\/\/doi.org\/10.1111\/1756-185X.12188","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"4866_CR70","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1002\/art.22808","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon WG, Symmons DPM, Lunt M, Watson KD, Hyrich KL, Silman AJ (2007) Serious infection following anti\u2013tumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56(9):2896\u20132904. https:\/\/doi.org\/10.1002\/art.22808","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04866-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04866-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04866-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:27:22Z","timestamp":1609547242000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04866-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4866"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04866-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}